EMA seeks stakeholder input on new reflection paper to reduce and replace non‑human primate use in medicines safety testing through 3Rs approaches.

EMA public consultation on non‑human primate use in safety testing

Non-human primate hand via pickpik.com (CC0)

The European Medicines Agency (EMA) has launched a public consultation on a draft “Reflection paper on non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation”.

The reflection paper provides an overview of the scientific and regulatory considerations for using non‑human primates (NHPs) in the safety testing of human medicinal products. It reviews current uses, highlights existing flexibility in applying the 3Rs principles (Replacement, Reduction and Refinement), and points to emerging alternatives that could further reduce or replace NHP use in the future.

NHPs should be used for regulatory safety testing only as a last resort. The document outlines current opportunities to reduce, refine or replace their use in pharmaceutical development and describes scientific advances that may soon gain broader regulatory acceptance.

Progress in novel, including non‑animal, approaches is scientifically and ethically essential and will depend on continued innovation, collaboration and proactive regulatory engagement.

The draft document is open for consultation, and stakeholders can provide input until 31 January 2026 via the EMA website: Non-human primates in safety testing of human medicinal products and opportunities for 3Rs implementation – scientific guideline.

News & Updates

You might also be interested in

European Parliament

European Parliament draft report urges a binding EU rare disease action framework

A legislative own initiative file in the Parliament’s new public health committee sets out what an EU “rare disease action framework” could look like — and why it could change how Europe measures progress for patients.
European Parliament Photograph

New European Parliament study maps options for an EU rare disease action plan

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
Publicaciones (1)

EU rare disease action plan- European Added Value Assessment

This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.
Rare Disease Day 2026 visual representation

One year of ERDERA: the European alliance built to accelerate rare disease research reports first results

28 February, across Europe and beyond: one year into delivery, ERDERA is advancing towards shorten diagnostic journeys and improved therapies for people living with a rare disease.

ERDERA's

search form